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Background/Aims: We evaluated the long-term outcome 
and clinical course of patients of nonsteroidal anti-inflam-
matory drug (NSAID)-induced small intestinal injury by per-
forming capsule endoscopy (CE). Methods: A multicenter 
retrospective study was conducted using data collected 
from the CE nationwide database registry, which has been 
established since 2002. Results: A total of 140 patients (87 
males; mean age, 60.6±14.8 years) from the CE nationwide 
database registry (n=2,885) were diagnosed with NSAID-in-
duced small intestinal injury and enrolled in our study. Forty-
nine patients (35.0%) presented with a history of aspirin use 
and an additional 49 (35.0%) were taking NSAIDs without 
aspirin. The most prominent findings after performing CE 
were multiple ulcerations (n=82, 58.6%) and erosions or 
aphthae (n=32, 22.9%). During the follow-up period (mean, 
15.9±19.0 months; range, 0 to 106 months), NSAID-induced 
small intestinal injury only recurred in six patients (4.3%). 
Older age and hypertension were positive predictive factors 
for recurrence. Conclusions: These results suggest that the 
recurrence of NSAID-induced small bowel injury was not fre-
quent in the presence of conservative treatment. Therefore, 
the initial diagnosis using CE and the medication history are 
important. (Gut Liver 2015;9:727-733)
Key Words: Anti-inflammatory agents, non-steroidal; Capsule 
endoscopy; Outcome
INTRODUCTION
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most 
commonly prescribed drugs worldwide. Their popularity attests 
to their efficacy as anti-inflammatory, analgesic, and antipyretic 
agents. An estimated 30 million people worldwide take NSAIDs 
daily.1 However, NSAID use is limited by their associated gas-
trointestinal (GI) toxicity. These drugs can cause serious injury 
to any part of the GI tract, including life-threatening complica-
tions such as bleeding or perforation.2 The worldwide preva-
lence of NSAID-associated gastric and duodenal ulcers is 9% to 
22%, with severe hemorrhage or perforation occurring in <1% 
of patients annually.3 
The serious problem of NSAID-induced small intestinal injury 
has recently become a topic of great interest to gastroenterolo-
gists, as capsule endoscopy (CE) and double-balloon endoscopy 
are available for detecting small intestinal lesions.4-8 NSAID-
induced small intestinal injury had been under-examined or 
even ignored in clinical situations prior to the availability of 
CE.9 Several CE studies have been performed in NSAID users. 
Goldstein et al.10 reported small bowel mucosal breaks in 55% 
of healthy volunteers who had taken naproxen for 2 weeks. 
Graham et al.11 performed CEs in patients with arthritis who had 
See editorial on page 697.
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been using NSAIDs for at least 3 months and reported the inci-
dence of small intestinal mucosal injury to be as high as 71%. 
Previous studies have focused mainly on the incidence 
of NSAID-induced small intestinal injury in short-term and 
chronic NSAID users or on the protective effect of concurrent 
medication in patients with NSAID-induced small intestinal in-
jury. However, data on the long-term outcome or natural course 
of NSAID-induced small intestinal injury are limited. Thus, 
we evaluated the long-term outcomes and clinical courses of 
patients diagnosed with NSAID-induced small intestinal injury 
based on the data from the Korean capsule endoscopy nation-
wide database registry.
MATERIALS AND METHODS
1. Korean capsule endoscopy nationwide database registry 
CE has been performed at 23 tertiary hospitals in Korea since 
2002 for 12 years, and the data have been registered in a com-
mon database. The database includes age, gender, indication 
for CE, key CE findings, diagnosis post CE, bowel preparation 
method, and the corrective therapies applied to the patients. 
2. CE procedure
Patients were examined using PilCam SB® (SB1/SB2) (Given 
Imaging, Yogneam, Israel) and MiroCam® (Intramedic, Seoul, 
Korea). Written informed consent was obtained from all patients 
before the procedure. CE was performed after a 12-hour fast and 
bowel preparation including ingestion of 2-L polyethylene gly-
col solution. The digital information recorded was downloaded 
onto a computer, and the images were analyzed using the pro-
prietary RAPID software (Given Imaging). 
3. Patients and data collection 
Subjects who were diagnosed with NSAID-induced small in-
testinal injury were identified from the database between Janu-
ary 2002 and August 2012. The term “NSAID-induced small 
intestinal injury” included the following: (1) all small intestinal 
injuries observed by CE; (2) history of NSAID use prior to the 
initial CE; (3) suspected small bowel injuries based on perform-
ing upper and lower GI endoscopy; and (4) exclusion of other 
causes of local disease (malignant tumors, inflammatory bowel 
disease, infectious disease, and so forth).12 
Among the 2,885 patients registered in the database, 140 
with NSAID-induced small intestinal injury from 14 centers 
were enrolled in the study. In addition to registry data, other 
data were collected via chart review and telephone interviews. 
The following data were collected: (1) presence or absence of 
underlying disease in the patient; (2) mode of bleeding; (3) drug 
history such as type of drug and period of medication; (4) labo-
ratory levels of hemoglobin and albumin; (5) follow-up period; 
(6) treatment method; (7) presence or absence of recurrence; and 
(8) any change in diagnosis during the follow-up period. 
The definition of recurrence of NSAID-induced small intes-
tinal injury was as follows: (1) history of diagnosis as NSAID-
induced small intestinal injury and recurring symptoms or ane-
mia and findings of the same lesion as that found upon initial 
diagnosis via CE or (2) history of diagnosis as NSAID-induced 
small intestinal injury and recurring symptoms or anemia and 
suspected recurrence based on negative findings on other ex-
aminations such as upper and lower GI endoscopy except CE. 
4. Statistical analysis
The results are presented as means±standard deviation or 
ranges for quantitative data and as frequencies (percentage) 
Fig. 1. Flow chart of the study sub-
jects.
NSAID, nonsteroidal anti-inflamma-
tory drug.
2,885 Database
140 NSAID-induced small intestinal injury
12 Changed diagnosis
5 Initial misdiagnosis
7 Change of diagnosis during follow-up
period
6 Recurred 110 Nonrecurred 12 Follow-up loss
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for categorical data. Data were analyzed using Student t-test 
and the chi-square test. All statistical anlyses were performed 
using the SPSS version 16.0 for Windows software (SPSS Inc., 
Chicago, IL, USA). A p-value <0.05 was considered to indicate 
significance. 
RESULTS
1. Enrollment and characteristics of the patients
Among the 2,885 patients registered in the database, 140 
patients from 14 centers were diagnosed with NSAID-induced 
small intestinal injury. Twelve patients were lost to follow 
up. Twelve of 140 patients who were initially diagnosed ex-
perienced a change in diagnosis during the follow-up period. 
Therefore, 116 patients were included in the disease recurrence 
analysis. Finally, six patients were diagnosed with recurrence of 
NSAID-induced small intestinal injury (Fig. 1).
Aspirin (n=49, 35.0%) and NSAIDs other than aspirin (n=49, 
35.0%) were the most frequently prescribed drugs in patients 
with NSAID-induced small intestinal injury. Ten percent (n=14) 
of patients were taking both aspirin and other NSAIDs concur-
rently. More than half of patients were taking medications for 
more than 3 months (n=73, 52.1%) (Fig. 2). 
The mean age of the patients was 60.6±14.8 years (range, 23 
to 90 years). The study group included 87 males (62.1%) and 
53 females (37.9%). The most common underlying disease was 
hypertension (42.9%). Diabetes (18.6%), cardiovascular disease 
(21.4%), and arthritis (19.2%) were also common. The total 
mean follow-up period was 15.9±19.0 months (range, 0 to 106 
months). Anemia was noted in patients with NSAID-induced 
small intestinal injury, but albumin levels were normal (Table 1).
2. CE findings of NSAID-induced small intestinal injury
The patients were examined by means of the PilCam SB® 
(85.0%) or MiroCam® (15.0%). The most common indication 
for CE was bleeding of unknown origin. Fifty-six patients were 
examined for obscure, overt GI bleeding (40%) and four patients 
were examined for obscure, occult GI bleeding (2.9%). The pres-
ence of melena (n=34, 24.3%) was the second most common in-
dication (Table 2). The most common key CE finding was ulcer-
ation (n=82, 58.6%). Erosions and mucosal erythema were also 
Fig. 2. Type of medication (A) and 
the period of nonsteroidal anti-infla-
mmatory drug (NSAID) prescription 
(B). Data are presented as number 
(%).
49 (35.0)
49 (35.0)
14 (10.0)
19 (13.6)
Aspirin
NSAID (without aspirin)
Aspirin NSAID
Unknown
Less than 1 wk
1 wk-3 mo
More than 3 mo
Unknown
73 (52.1)
42 (30.0)
14 (10.0)
11
(7.9)
A B
Table 1. Clinical Characteristics of Nonsteroidal Anti-Inflammatory 
Drug-Induced Small Intestinal Injury
Characteristic Value
Age, yr
Male:female
Type of capsule endoscopy
   MiroCam®
   PilCam SB®
Comorbidities 
   Hypertension
   Diabetes
   Cardiovascular disease
   Cerebrovascular disease
   Chronic renal disease
   Arthritis
Follow-up period, mo
Initial blood test
   Hemoglobin, g/dL
   Albumin, g/dL
60.6±14.8
87 (62.1):53 (37.9)
21 (15.0)
119 (85.0)
60 (42.9)
26 (18.6)
30 (21.4)
12 (8.6)
8 (5.7)
27 (19.2)
15.9±19.0 (0–106)
9.6±2.7
3.7±0.6
Data are presented as mean±SD (range) or number (%).
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common (Fig. 3). Other lesions found in patients with NSAID-
induced small intestinal injury included luminal narrowing and 
stenosis, small bowel submucosal tumor, and small bowel pol-
yps (Table 3). The lesions were located frequently in the jejunum 
(n=74, 52.8%) and ileum (n=39, 27.9%). 
3. Treatment for NSAID-induced small intestinal injury
Most patients stopped NSAID therapy after diagnosis (n=91, 
71.1%). However, 28 patients (21.9%) continued to take NSAIDs 
following their diagnosis. Aspirin was the most common medi-
cation used among the patients who continued to take NSAIDs. 
Following diagnosis, most of the patients were treated by non-
invasive methods, such as simply discontinuing NSAID therapy 
(n=13, 10.2%) or were prescribed additional medication (n=44, 
34.4%), or both (n=52, 40.6%). Only three cases (2.3%) under-
went endoscopic treatment, and none of the patients had sur-
gery (Fig. 4). A proton pump inhibitor (PPI) (n=61, 63.6%) was 
most commonly prescribed additional medication. Rebamipide 
(n=21, 21.9%), an H2-receptor blocker (n=18, 18.6%), and miso-
prostol (n=10, 10.4%) were also commonly prescribed therapeu-
tic drugs in patients with NSAID-induced small intestinal injury.
4. Clinical features of recurrent and nonrecurrent cases of 
NSAID-induced small intestinal injury 
Only six NSAID-induced small intestinal injury cases recurred 
during the follow-up period. The mean age of the recurrent 
Table 2. Indication of Capsule Endoscopy in Patients with Nonsteroi-
dal Anti-Inflammatory Drug-Induced Small Intestinal Injury
Indication No. (%)
Obscure overt GI bleeding
Melena
Hematochezia
Abdominal pain
Anemia
Obscure occult GI bleeding
Etc. (diarrhea, abnormal findings in CT, 
  small bowel series)
56 (40.0)
34 (24.3)
15 (10.7)
14 (10.0)
7 (5.0)
4 (2.9)
10 (7.1)
GI, gastrointestinal; CT, computed tomography.
Table 3. The Clinical Features of Six Recurrent Cases of Nonsteroidal Anti-Inflammatory Drug-Induced Small Intestinal Injury
Case  
no.
Sex/
age, yr
Type of 
NSAID
Symptoms  
when recurred
Examination  
performed  
when recurred
Treatment  
when recurred
Sort of treatment  
medication
Period until  
recurrence, mo
1
2
3
4
5
6
M/67
F/62
F/69
M/69
M/74
M/60
Aspirin
Aspirin+NSAID 
Aspirin
Aspirin
Aspirin
Aspirin
Melena
Hematochezia
Melena
Melena
Anemia
Anemia
EGD, CFS
EGD, CFS
None
EGD, CFS
None
EGD, CFS, CE
Add medication
Add medication
Add medication
Add medication
Add medication
Add medication
PPI
Rebamipide
Iron supplement
PPI
Iron supplement
Iron supplement
22
28
14
1
27
9
NSAID, nonsteroidal anti-inflammatory drug; M, male; EGD, esophagogastroduodenoscopy; CFS, colonofiberoscopy; PPI, proton pump inhibitor; F, 
female; CE, capsule endoscopy.
Fig. 3. Capsule endoscopic findings of nonsteroidal anti-inflammatory drug-induced small intestinal injury. Erosions (A), ulcerations (B), and 
strictures (C) were noted.
A B C
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cases was 66.8±5.1 years (range, 60 to 74 years). Four of the 
six patients revisited the hospital complaining of symptoms of 
bleeding, and recurred or continued anemia was found in two 
cases. Of the recurring patients, only one underwent CE again. 
The majority of patients were supposed to recur with NSAID-
induced small intestinal injury based on negative findings in 
studies other than CE. All six recurrent cases continued to take 
aspirin after initial diagnosis, but, only 21.2% of patients con-
tinued to take aspirin in nonrecurrent cases (p=0.001). Aspirin 
was the most commonly prescribed medication for the recurrent 
cases. One patient was taking a NSAID other than aspirin due to 
severe pain from arthritis. Cardiovascular disease, such as isch-
emic heart disease, was the reason for taking medication in four 
of six recurrent cases. All patients recovered by conservative 
management without endoscopic treatment or surgery (Table 3).
The clinical characteristics of cases involving recurrence and 
nonrecurrence were observed (Table 4). Mean age was signifi-
cantly higher in recurrent than in nonrecurrent cases (66.8±5.1 
years vs 60.1±14.8 years, p=0.023). No significant difference 
was observed in the male to female distribution. The initial drug 
Fig. 4. Treatment modalities of patients with nonsteroidal anti-
inflammatory drug (NSAID)-induced small intestinal injury. Data are 
presented as number (%).
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Table 4. Comparison of Recurrent and Nonrecurrent Patients
Variable Nonrecurrent cases (n=110) Recurrent cases (n=6) p-value
Age, yr
Male:female 
Initial drug history 
   Aspirin
   NSAID (except aspirin) 
   Aspirin+NSAID 
Continuance of NSAID
   Discontinue
   Continue
Underlying disease 
   Hypertension 
   Diabetes mellitus
   Cardiovascular disease 
   Chronic renal disease 
   Arthritis 
   Cerebrovascular disease
Hemoglobin level  
Key findings of capsule endoscopy 
   Ulcer
   Erosion
   Mucosal erythema
   Mucosal spotty hemorrhage 
   Diffuse small bowel bleeding
   Angiodysplasia
60.1±14.8
65:45
38 (34.5)
42 (38.2)
12 (10.2)
80 (67.8)
25 (21.2)
47 (42.7)
17 (15.5)
24 (21.8)
4 (3.6)
24 (21.8)
9 (8.2)
9.62±2.59
69 (62.7) 
25 (22.7) 
7 (6.4) 
3 (2.7)
0   
0  
66.8±5.1
4:2
4 (66.7)
2 (33.3)
0 
0 
6 (100.0)
6 (100.0)
3 (50.0)
3 (50.0)
1 (16.7)
2 (33.3)
     0 
8.35±2.31
2 (33.3)
1 (16.7)
     0
1 (16.7)
1 (16.7)
1 (16.7)
0.023
0.949
0.349
0.001
0.023
0.092
0.279
0.304
0.789
0.742
0.244
0.001
Data are presented as mean±SD or number (%).
NSAID, nonsteroidal anti-inflammatory drug.
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history was not different between the two groups. However, 
taking aspirin was more common among recurrent cases. But, 
the difference was not statistically significant. Of the recurrent 
cases, one patient who was initially diagnosed with NSAID-in-
duced small intestinal injury due to taking an NSAID because of 
arthritis changed medication to aspirin after suffering ischemic 
heart disease. Including this case, the majority of recurrent pa-
tients were taking aspirin. Hypertension was more common in 
recurrent cases (42.7% vs 100%, p=0.023), but other underlying 
diseases were not different. As the key CE findings were signifi-
cantly different between recurrent and nonrecurrent cases, ul-
cerations and erosions were more common in nonrecurrent than 
recurrent cases. Ulcerations were commonly noted in recurrent 
cases; however, other findings, such as diffuse small bowel 
bleeding and mucosal spotty hemorrhage, were also noted.
5. Change in diagnosis
Twelve patients who were initially diagnosed with NSAID-
induced small intestinal injury had their changed diagnosis 
after other diseases were identified during the follow-up period. 
Among these 12 cases, five were due to initial misdiagnosis. 
Chiefly, errors in drug history of the patients resulted in the 
misdiagnosis. The adjusted diagnoses were as follows: angio-
dysplasia, ischemic enteritis, tuberculosis enteritis, Dieulafoy’s 
lesion, gastrointestinal stromal tumor, idiopathic ulceration, 
Behçet’s disease, and ileal erosion.
DISCUSSION
NSAIDs are one of the most commonly prescribed drugs due 
to their analgesic and anti-inflammatory properties. They are 
used to reduce fever and treat pain or inflammation caused by 
chronic conditions such as rheumatoid arthritis and osteoarthri-
tis.13 Previous studies have focused primarily on their upper GI 
events. NSAID-induced small intestinal injury has gained more 
attention due to the introduction of new diagnostic modalities, 
such as CE and double-balloon endoscopy.9 However, little is 
known about the mechanism of NSAID-induced small intestinal 
injury. Our study focused not only on the prevalence and char-
acteristics of patients diagnosed with NSAID-induced small in-
testinal injury but included data accumulated during long-term 
observations of these patients, such as recurrence and changes 
in diagnoses.
The number of patients undergoing CE for various reasons is 
increasing. However, CE remains a relatively rarely performed 
examination. Thus, the Korean Gut Image Study Group founded 
the capsule endoscopy nationwide database registry in 2002 to 
accumulate and analyze clinical data of CE. The Study Group 
for Double-Balloon Endoscopy reported that NSAID-induced 
small intestinal injury occurred in 51% of the patients taking 
NSAIDs, based on the registry data accumulated during a 2-year 
period beginning in 2008.14 However, this study did not include 
long-term follow-up data. Our study is the first report to ana-
lyze the data collected from the nationwide database registry of 
CE and include long-term follow-up data. 
Only six cases (4.3%) in the capsule endoscopy nationwide 
database registry in Korea recurred as NSAID-induced small in-
testinal injury during the follow-up period from 2002 to 2012. 
Most of these patients recovered without endoscopic or surgi-
cal intervention. Patients were treated with medications even 
after recurrence. Initial drug history, initial hemoglobin level, 
and the treatment options were not different between recurrent 
and nonrecurrent cases. However, older age and hypertension 
were positive predictive factors for recurrence. More atypical CE 
findings, such as diffuse small bowel bleeding, mucosal spotty 
hemorrhage, and angiodysplasia were observed in the recurrent 
group. Thus, older patients, those with hypertension, and atypi-
cal CE findings were monitored carefully because of the high 
probability of recurrence regardless of drug history or treatment 
options. Continuous use of aspirin was the most significant fac-
tor to cause recurrence. But recurrence of NSAID bleeding is not 
frequent and most of recurred bleeding can be managed conser-
vatively similar to first episode of bleeding.
Among the 140 patients diagnosed with NSAID-induced 
small intestinal injury, 12 were diagnosed with another disease 
during the follow-up period. Five of these cases were misdi-
agnosed initially. Mistakes in taking the drug history were the 
major cause of misdiagnosis. Seven cases initially diagnosed as 
NSAID-induced small intestinal injury were changed to other 
diseases. After its diagnosis, NSAID-induced small intestinal 
injury reacted well to medication and conservative treatment, 
and the recurrence rate was relatively low. Initial history taking 
was important because the diagnosis of NSAID-induced small 
intestinal injury is largely dependent on drug history. 
It is important to evaluate the long-term efficacy of the drugs 
prescribed for patients with NSAID-induced small intestinal 
injury. Administration of NSAIDs is known to induce upper GI 
complications, and PPIs prevent their occurrence.15,16 However, 
to date, no medications that could prevent or heal NSAID-in-
duced small intestinal injuries were available. PPIs are the most 
effective medications for gastroduodenal bleeding and ulcers 
but cannot be expected to be clinically efficacious for small in-
testinal mucosal injury, as acid is not secreted into the small in-
testine.17 PPIs worsen NSAID-induced small intestinal injury in 
animals, and emerging evidence indicates that such worsening 
may occur in some humans.18,19 Managing patients with NSAID-
induced small intestinal injury relies empirically on misoprostol 
and rebamipide. Misoprostol has demonstrated positive thera-
peutic effects in NSAID-induced small intestinal injury.20 Niwa 
et al.17 found that subjects who received an NSAID and placebo 
demonstrated a significantly greater number of small intestine 
mucosal injuries than those who received rebamipide. However, 
these studies were relatively small, and therapeutic efficacy was 
evaluated over the short-term. In the present study, the PPI, re-
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bamipide, H2 blocker, and misoprostol were the most commonly 
prescribed drugs in patients with NSAID-induced small intes-
tinal injury. When the influence of the drugs on disease recur-
rence was evaluated, no significant differences were observed. 
To our knowledge, this is the first study about the long-term 
outcome of NSAID-induced small intestinal injury assessed by 
CE based on a nationwide multicenter data registry.
Several limitations of this study should be discussed. First, it 
was a retrospective analysis. We collected data from the cap-
sule endoscopy nationwide database registry. Furthermore, we 
reviewed the charts of patients and conducted telephone inter-
views to collect data. Hence, recall error could have influenced 
the results. Second, we did not assess the severity of NSAID-in-
duced small intestinal injury in each patient. Recurrence may be 
dependent on disease severity at original presentation. However, 
we are uncertain whether the recurrence rate was dependent on 
the severity of NSAID-induced small intestinal injury. Third, a 
complete follow-up of all patients was not possible. Therefore, 
116 of 140 patients were enrolled in this analysis of recurrence. 
And all cases with anemia or occult obscure gastrointestinal 
bleeding did not undergo follow-up complete blood count regu-
larly after the first presentation. So, we think there were more 
current cases that did not be revealed. 
In conclusion, the recurrence of NSAID-induced small intes-
tinal injury was infrequent regardless of conservative manage-
ment, such as discontinuing NSAID therapy or administration of 
additional medications. Hence, an initially accurate diagnosis by 
performing CE and a thorough medication history were impor-
tant. Although changes in diagnosis following an initially ac-
curate diagnosis were infrequent; however, some patients were 
subsequently diagnosed with another disease during the follow-
up period. Therefore, differential diagnoses should be considered 
carefully when evaluating NSAID-induced small intestinal in-
jury. 
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